



## The Future of Surgery is Clear.

FDA-cleared anti-fog technology powered  
by breakthrough surface energy science

INVESTOR PRESENTATION  
Q4 2025

Privileged and Confidential



# Lens Fogging Compromises Nearly Every Surgery



Every minute an endoscope fogs, the operating room loses time and money, but also increase safety risks:

- 5–10 minutes lost per interruption
- \$46–\$133 per minute of OR time wasted
- This happens thousands of times per day per OR

## ROOT CAUSE



Temperature Differences



Humidity



Bodily Fluids

# The First FDA-Cleared Anti-Fog Gel That Keeps Surgery Moving.




Uninterrupted Surgeries  
No scope withdrawals

Efficiency Gains  
Saves hospitals up to \$24K per 3-hour procedure in OR time.

Clinically Safe  
FDA-cleared, sterile, biocompatible, and compatible with all surgical equipment.

Plug-and-Play Simplicity  
One “dip, wipe, and go” step for every surgeon in every procedure.



# Fog-Free Surgery: The Inevitable Standard of Care



Targeting a \$12B Market Growing to \$25B by 2033

## Capture a Category at Inflection.

Annual procedure growth of 5-7% drives the endoscopy market from \$12B to \$25B by 2033.

KnoxFog enables the transition to fog-free surgery as standard of care.

U.S. MARKET			
Medical Devices <sup>1</sup>			
<b>2025</b>	<b>\$200.14B</b>	<b>2030</b>	<b>\$266.64B</b>
With a CAGR of 5.9% from 2025 to 2030 Medical Technology <sup>2</sup>			
<b>2025</b>	<b>\$232.29B</b>	<b>2030</b>	<b>\$304.23B</b>
With a CAGR of 5.54% from 2025 to 2030			
GLOBAL MARKET			
Endoscopy Equipment <sup>3</sup>			
<b>2023</b>	<b>\$11.9B</b>	<b>2033</b>	<b>\$24.7B</b>
With a CAGR of 7.6% from 2024 to 2033			

Surface Energy Driven Medical Device Technologies

U V O N E H Y G I E N I C S

Privileged and Confidential

<sup>1</sup> [statista.com/outlook/hmo/medical-technology/medical-devices/united-states](https://www.statista.com/outlook/hmo/medical-technology/medical-devices/united-states)

<sup>2</sup> [statista.com/outlook/hmo/medical-technology/united-states](https://www.statista.com/outlook/hmo/medical-technology/united-states)

<sup>3</sup> [media.market.us/endoscopy-equipment-market-news/](https://www.media.market.us/endoscopy-equipment-market-news/)

# The \$11B Problem Hospitals Can't Ignore.



\$12B Market Growing to \$25B by 2033 - Procedure volumes are growing at 5-7% annually as minimally invasive surgery becomes standard across specialties:



- Endoscopy is one of the fastest-growing categories in medical devices - every procedure depends on clear visibility
- Fog delays occur in 60%+ of procedures, directly impacting the metrics hospitals are rewarded for speed, safety and standardization
- KnoxFog aligns with procurement priorities, positioning *fog-free* as essential infrastructure, not optional equipment

KnoxFog's clinically validated effectiveness ensures superior time savings compared to competing products in the fast-growing medical devices and endoscopy market.

Surface Energy Driven Medical Device Technologies

UV ONE HYGIENICS

Privileged and Confidential

5 / 15

1 [statista.com/outlook/hmo/medical-technology/medical-devices/united-states](https://www.statista.com/outlook/hmo/medical-technology/medical-devices/united-states)

2 [statista.com/outlook/hmo/medical-technology/united-states](https://www.statista.com/outlook/hmo/medical-technology/united-states)

3 [media.market.us/endoscopy-equipment-market-news/](https://www.media.market.us/endoscopy-equipment-market-news/)



The **Only** Solution That  
Saves Lives and  
Operating Room Costs

---

KnoxFog delivers 30× longer  
clarity and up to 90% cost  
savings turning every  
minute of surgery into  
profit instead of risk.



# Go-To-Market



## Ready

UV ONE's powerhouse sales team ensure a strong entry in to the market. Our team is firmly established in the VA Hospital procurement system with a strong track record of VA sales. Our team is also recognized for their sales achievements in the non-government healthcare sales space.

**VA Hospitals**  
Federal Procurement Entry

**Hospital Systems**  
Volume Scale

**Ambulatory Surgery Centers**  
High-Margin Procedures

**Specialty Medical Offices**  
Market Breadth

Four sales channels are ready to launch with highly experienced specialized medical sales teams ready to go as soon as manufacturing begins.

# DISTRIBUTION STRATEGY



Four-channel strategy delivers \$28M+ Year 1 revenue from 0.58% market capture

## YEAR 1 REVENUE MODEL

### VA CHANNEL

- 40,000 procedures | \$6M revenue

### COMMERCIAL CHANNELS

Hospital Systems + ASCs + Specialty)

- 147,500 procedures | \$22M revenue

**TOTAL: \$28,125,000**

### COMPETITIVE ADVANTAGES

#### De-risked execution

- SDVOSB partner & reps have existing relationships
- Surgeons already use anti-fog solutions

### ECONOMIC SUPERIORITY

- 90% cost savings vs. CLEARIFY (\$1,470/procedure)
- 44-63% cost savings vs. FRED

### DEFENSIBLE POSITION

- FDA-cleared, 3+ hour effectiveness (30x longer)
- Four channels eliminate concentration risk

### INVESTMENT HIGHLIGHTS

#### \$1.5M achieves full commercialization

- GMP manufacturing complete
- Performance-based sales = zero fixed cost 20 experienced surgical device reps across all channels
- Month 1-3: All channels launch | Year 1: \$28M+ revenue

# Leadership



**Dora Suppes**

CHIEF EXECUTIVE OFFICER



**Mark Russell-Hill**

CHIEF OPERATIONS OFFICER



**Cisco Schipperheijn**

CHIEF TECHNICAL OFFICER

Dora Suppes CEO: Veteran in healthcare and tech commercialization with 40+ years of leadership.

Dora's expertise in sterilization and anti-fog coatings, combined with her ability to navigate the complex FDA clearance process, was instrumental in establishing UV One and its vision to make advanced medical technologies universally accessible.

Mark Russell-Hill COO: Optical systems engineer and inventor with deep expertise in light and surface energy.

Mark bridges technical innovation with scalable operations. His meticulous operational processes and systems-thinking were instrumental in scaling UV One's technology from laboratory innovation to market success.

Cisco is recognized for his strategic vision and technical expertise in developing disruptive technologies with long-term viability.

Serial technology executive specializing in disruptive medical and diagnostic devices. Cisco brings strategic foresight and technical rigor, ensuring long-term defensibility and predictable ROI.

*Surface Energy Driven Medical Device Technologies*

UV ONE HYGIENICS

Privileged and Confidential

# Leadership



**Dr. Nicole Herbots**  
CHIEF SCIENCE OFFICER

Dr. Herbots consults on laboratory research, device design, and the transition of innovations into full-scale FDA-approved manufacturing.

Dr. Herbots has founded over a dozen medical device companies built on her patented technologies, with expertise spanning anti-fog coatings, diagnostic devices, and bio-compatible implant surfaces.



**Dennis Gross**  
PRESIDENT / SALES

Dennis brings more than 40 years of global experience in sales, finance, and technology innovation.

His entrepreneurial drive, combined with a passion for philanthropy and service, including time in the New York National Guard and U.S. Army OCS, positions him as a critical leader guiding UV One Hygienics' growth and commercialization strategy.



**Scott Harvey**  
VICE PRESIDENT MEDICAL SALES

Scott brings over 15 years of expertise in medical device distributorship, specializing in spine, foot and ankle, and biologics markets.

His proven track record includes consistently exceeding sales quotas, serving as Chief Commercial Officer and VP of Sales at Echelon Medical Corp., founding and leading Peritus Ortho, and acting as an independent distributor for Quest Orthopedics.

*Surface Energy Driven Medical Device Technologies*

UV ONE HYGIENICS

Privileged and Confidential

# Competitive Landscape



KnoxFog outperforms costly and unreliable competitors by delivering immediate, lasting clarity without reapplication – saving hospitals up to \$24K in Operating Room time during a single 3-hour procedure.

With FDA clearance, trade secret protection, and patent filings underway, it offers 30x longer effectiveness in a simple, biocompatible solution that integrates seamlessly into surgical workflows.

	KnoxFog	FRED	CLEARIFY
	\$150 per vial with no reapplication for 3+ hours	\$20 to \$23 per use + frequent reapplication needed	\$135 per use + reapplication needed every 15 minutes
1-Hour Procedure	\$150 (1 Application)	\$60 to \$90 (3 to 4 Applications)	\$540 (4 Applications)
2-Hour Procedure	\$150 (1 Application)	\$120 to \$180 (6 to 8 Applications)	\$1,080 (8 Applications)
3-Hour Procedure	\$150 (1 Application)	\$180 to \$270 (9 to 12 Applications)	\$1,620 (12 Applications)

## Key Insights


KnoxFog delivers up to 90% cost savings compared to CLEARIFY, breaking even after just over a single use. Unlike CLEARIFY, which requires costly reapplications and repeated interruptions, KnoxFog ensures uninterrupted procedures with superior efficiency and clarity.

# Roadmap



\$1.5m completes GMP manufacturing set up and production of first batch of 20k units.

Achieves full commercialization and profitability.



# Financial Projection



FDA-Cleared Medical Scop Anti-Fog Solution	
Market Assumptions	
Total U.S. Market (Annual Procedures)	75,000,000.00
Price per Procedure	\$ 150.00
Competitor Base Price	\$ 135.00
Competitor Total Cost ( 2 to 3 Applications)	\$ 270.00 – \$ 405.00
Your Cost Advantage	44% – 63%

Conservative Scenario				
Year	Market Share	Procedures	Price / Procedure	Annual Revenue
Year 1	0.25%	187,500.00	\$ 150.00	\$ 28,125,000.00
Year 2	0.75%	562,500.00	\$ 150.00	\$ 84,375,000.00
Year 3	1.50%	1,125,000.00	\$ 150.00	\$ 168,750,000.00
Year 4	2.50%	1,875,000.00	\$ 150.00	\$ 281,250,000.00
Year 5	3.50%	2,625,000.00	\$ 150.00	\$ 393,750,000.00
5-Year Total		6,375,000.00		\$ 956,250,000.00

Moderate Scenario				
Year	Market Share	Procedures	Price / Procedure	Annual Revenue
Year 1	0.50%	375,000.00	\$ 150.00	\$ 56,250,000.00
Year 2	1.50%	1,125,000.00	\$ 150.00	\$ 168,750,000.00
Year 3	3.00%	2,250,000.00	\$ 150.00	\$ 337,500,000.00
Year 4	5.00%	3,750,000.00	\$ 150.00	\$ 562,500,000.00
Year 5	7.00%	5,250,000.00	\$ 150.00	\$ 787,500,000.00
5-Year Total		12,750,000.00		\$ 1,912,500,000.00

Surface Energy Driven Medical Device Technologies

U V O N E H Y G I E N I C S

Privileged and Confidential

# The Ask



We're raising \$1.5M to produce 20,000 units, launch commercially in 200+ hospitals, and create profitability path within 18 months

---



**\$1,500,000**  
FUNDING ASK



**Dora Suppes**  
CHIEF EXECUTIVE OFFICER



480-221-4712



dora@uvonetech.com



uvonetech.com/



linkedin.com/in/dora-suppes-0934439b/



UV ONE Hygienics, Inc.  
Phoenix, Arizona, USA

# Appendix

# KnoxFog Technology and IP



KnoxFog secures its competitive moat with a dual IP strategy that leverages patents for credibility and trade secrets for perpetual protection thereby ensuring unmatched performance and market defensibility.

The core breakthrough is a biocompatible, hyper-hydrophilic gel with a proprietary natural polymer that delivers a robust, long-lasting anti-fog barrier on endoscope lenses. KnoxFog's single-dip, wipe-and-go application offers 30x longer clarity than competitors while maintaining biocompatibility, safety, and seamless integration across all surgical equipment.

This innovation is fortified by a balanced IP approach: patents accelerate market credibility while trade secrets provide indefinite protection, rapid market entry, and a sustained competitive edge. Robust security, confidentiality agreements, and strategic IP planning further mitigate risks of disclosure or misappropriation.

## KNOXFOG TECHNOLOGY AND IP FORTRESS – DUAL PROTECTION STRATEGY

Core Innovation	Trade Secret Strategy	Risk Mitigation
<ul style="list-style-type: none"> <li>Biocompatible gel with hyper-hydrophilic formulation</li> <li>30x longer clarity, single application</li> <li>Sterile, pH neutral, non-toxic, integrates with all equipment</li> </ul>	<ul style="list-style-type: none"> <li>Keeps core process and formulation undisclosed</li> <li>Provides perpetual protection</li> <li>Faster time-to-market by bypassing lengthy patent prosecution</li> </ul>	<ul style="list-style-type: none"> <li>Robust security and confidentiality agreements</li> <li>Strategic planning to prevent parallel development</li> <li>Balanced patent + trade secret approach</li> </ul>

## OTHER TECH.

Peer Reviewed Surface Energy based Medical IP:

**ClearRetina™** is a biocompatible hyper hydrophilic gel used to prevent fogging in retina surgeries in patients who have had cataract surgery.

**InnovaBug**, a low volume, fast and accurate handheld blood analysis unit for pathogen detection.

**InnovaStrip™** is a low volume, fast, accurate, handheld comprehensive Small Volume Blood Diagnostics (SVBD) testing unit.

